Metachronous contralateral breast cancer: An analysis of risk factors and prognosis in 42,670 women in Sweden.

Vichapat,; Garmo, Hans; Holmqvist, Marit; Holmberg, L; Liljegren, G; Wärnberg, Fredrik; Lambe, Mats; Fornander, Tommy; Adolfsson, Jan; Lüchtenborg, Margreet

doi:10.1200/jco.2011.29.15_suppl.1568

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Supporting this are studies showing lymph-node-status of BC1 to influence risk of CBC and the time-interval between tumors to affect prognosis (4,5). In addition, genetic comparisons…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy

Alkner¹,

Ehinger²,

Bendahl³

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.Alkner, Sara; Ehinger, Anna; Bendahl, Pär-Ola; Rydén, Lisa; Fernö, Mårten Link to publication Citation for published version (APA): Alkner, S., Ehinger, A., Bendahl, P-O., Rydén, L., & Fernö, M. (2015). Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy. European Journal of Cancer, 51(16), 2304 -2313 . DOI: 10.1016 /j.ejca.2015 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Role of the Funding Sources:None of the funding sources had any impact on study design; the collection, analysis and interpretation of data; the writing of the report; or in the decision to submit the article for publication.3 Abstract Aim: A contralateral breast cancer (CBC) is today treated as an independent primary tumor, although recent data suggest risk and prognosis of CBC to be influenced by characteristics of and treatment given for the first tumor (BC1). We hereby investigate phenotypical and prognostic features of the second tumor (BC2) in relation to prior endocrine treatment and radiotherapy.Methods: From a well-defined population-based cohort of CBC-patients, we have constructed a unique tissue-microarray including 600 pairs of primary tumors and CBCs.Breast cancer mortality was primary end-point for prognosis. Results: Both estrogen receptor (ER) status and stage was strongly correlated between BC1and BC2 within CBC-pairs. Although BC2 had the highest prognostic impact, BC1 continued to influence prognosis after diagnosis of CBC. Patients diagnosed with two high stage tumors within a short time-interval had a particularly bad prognosis. Prior endocrine therapy and radiotherapy both correlated to ER-negativity of BC2. An ER-negative BC2 was associated with an inferior prognosis compared to an ER-positive BC2 regardless of ER-status of BC1 or prior endocrine therapy. Conclusions:Our results suggest that both the residual prognostic impact of BC1, the possibility of contralateral metastasis, as well as prior treatment given, need to be considered when determining appropriate diagnostic work-up and treatment of CBC. In addition, radiation to the contralateral breast and risk of inducing CBC with an aggressive ER-negative phenotype should be considered when establishing new radiation treatm...

show abstract

“…Supporting this are studies showing lymph-node-status of BC1 to influence risk of CBC and the time-interval between tumors to affect prognosis (4,5). In addition, genetic comparisons…”

Section: Discussionmentioning

confidence: 88%

“…A CBC is today treated as a new independent primary tumor, although recent data suggest that the second tumor (BC2) may in some cases be a metastasis of the first (BC1) (4,5). In addition, CBC diagnosed in close connection to prior adjuvant treatment is presumably resistant to the treatment given.…”

Section: Introductionmentioning

confidence: 99%

Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy

Alkner¹,

Ehinger²,

Bendahl³

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…When the survival rates of unilateral and BBCs were compared, according to Jobsen et al [20], distant metastasis was more common in patients with BBC; the 5-year and 10-year survival rates were 82.1% and 41% in BBC and 91.4% and 84% in unilateral breast cancer, respectively. Some studies indicated that SBBC is associated with a worse prognosis [21][22][23][24], while others stated that SBBC has a similar or even better prognosis compared with MBBC [25,26].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Clinicopathologic Features and Outcomes Between Synchronous and Metachronous Bilateral Breast Cancer

Kim¹,

Won²

2023

J Breast Dis

View full text Add to dashboard Cite

Purpose: Bilateral breast cancer (BBC) can be divided into two concurrent lesions, depending on the time of occurrence of primary cancer and secondary tumors after treatment of the primary cancer. This study aimed to compare the clinicopathological characteristics and results of synchronous BBC (SBBC) and metachronous BBC (MBBC).Methods: Data of patients diagnosed with breast cancer at Wonkwang university Hospital between October 1991 and October 2021 were retrospectively reviewed. Data of 3,259 patients who were diagnosed with malignant neoplasm of the right or left breast were reviewed. The tumor was defined as SBBC when another cancer was identified as BBC simultaneously or within six months after the primary breast cancer, and as MBBC when another cancer was identified after six months. Among patients with BBC, 31 had SBBC and 32 had MBBC.Results: In SBBC patients, the median age was 59.9 years, and the condition was diagnosed 3.3 years later compared with MBBC. The primary and secondary tumors of SBBC had lower disease stage, even when diagnosed late. Except for tumor, node, and metastasis stage, MBBC showed more invasive ductal carcinoma, while SBBC showed relatively more ductal carcinoma <i>in situ</i> in both primary and secondary tumors compared with MBBC. In addition, SBBC showed lower hormone receptor positivity rates and Ki-67 levels compared with MBBC. MBBC patients showed a higher survival rate compared with SBBC patients. MBBC is associated with higher overall survival rate compared with SBBC, and its prognosis is not worse compared with that of unilateral breast cancer. In the case of secondary tumor that develops in the contralateral breast without evidence of metastasis, the survival rate is similar to that of unilateral breast cancer, while the treatment is similar to that of primary tumor.Conclusion: As those with SBBC have a worse survival, these patients will require more medical attention; meanwhile, MBBC requires an active treatment approach that is equivalent to that for unilateral breast cancer.

show abstract

Metachronous contralateral breast cancer: An analysis of risk factors and prognosis in 42,670 women in Sweden.

Cited by 2 publications

References 0 publications

Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy

Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy

Comparison of Clinicopathologic Features and Outcomes Between Synchronous and Metachronous Bilateral Breast Cancer

Contact Info

Product

Resources

About